The Comparison of FLOT and DCF Regimens as Perioperative Treatment for Gastric Cancer
ONCOLOGY, cilt.103, sa.2, ss.128-133, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 103 Sayı: 2
- Basım Tarihi: 2025
- Doi Numarası: 10.1159/000540517
- Dergi Adı: ONCOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL
- Sayfa Sayıları: ss.128-133
- Gazi Üniversitesi Adresli: Evet
Özet
Introduction: Locoregional gastric cancer is a still serious problem and perioperative treatments may improve the success of management. Different regimens were examined. The present study purposed to compare the efficacy of fl uorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) and docetaxel-cisplatin-fluorouracil (DCF) regimens. Methods: A retrospective multicenter study assessed the patients with loco regional gastric cancer. There are 240 patients (137 DCF, 103 FLOT). Survival rates were compared. Results: Demographic features were similar between the two groups, but the time period was different. The FLOT group had 7.8% pathological complete response, while the DCF group did not. Disease-free survival was longer in the FLOT than in the DCF group (median not reached - 13.94 months, respectively). Median overall survival was similar (30.9 vs. 37.8 months), but median follow-up affected the analysis. Survival for 36 months was 63% for the FLOT group and 40% for the DCF group (log-rank; p = 0.015). Conclusion: FLOT regimen was superior to DCF regimen for response and survival rates. DCF is a historical approach. Long-term follow-up period is needed for FLOT treatment. (c) 2024 S. Karger AG, Basel